Assessing TB infection control practices in Malawi: research application and implications for the regional response
Tuberculosis (TB) is the 9th leading cause of death worldwide.1 While TB mortality and incidence are decreasing, there are still significant gaps in detection and treatment.2 One in four new TB cases occurred in Africa in 2016, and co-infection with HIV is a notable challenge, with 34% of those infected with TB on the continent also living with HIV.3 While people living with HIV are a particularly vulnerable population due to their compromised immunity, health care workers (HCWs) are also at higher risk due to frequent and sustained exposure to th
Emerging superbugs that can resist even the most powerful antibiotics and medical treatments present one of the biggest global health threats in history.
When manifested in a simple throat infection, a lingering stomach bug or a serious disease like tuberculosis, resistance to medicine is tremendously threatening. Global development partners must move faster to contain the threat of antimicrobial resistance before it escalates to claim millions of lives around the world.
Barriers and facilitators to the uptake of tuberculosis diagnostic and treatment services by hard-to-reach populations in countries of low and medium tuberculosis incidence: a systematic review of qualitative literature
Tuberculosis disproportionately affects hard-to-reach populations, such as homeless people, migrants, refugees, prisoners, or drug users. These people often face challenges in accessing quality health care. We did a systematic review of the qualitative literature to identify barriers and facilitators to the uptake of tuberculosis diagnostic and treatment services by people from hard-to-reach populations in all European Union (EU), European Economic Area, EU candidate, and Organisation for Economic Co-operation and Development countries.
TB partners, patients ask: How does a bacterium responsible for nearly a third of drug-resistance deaths not make list of R&D priority pathogens?
Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics
The World Health Organization was requested by Member States to develop a global priority pathogens list (global PPL) of antibiotic-resistant bacteria to help in prioritizing the research and development (R&D) of new and effective antibiotic treatments. To date, the selection of pathogens for R&D activities has been largely guided by small and large pharmaceutical companies according to a variety of parameters, such as perceived/unmet medical need, pressure of investors, market size, scientific discovery potential, and availability of specific technologies.